Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting a specific share transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details an increase in the notional interest in Ordinary Shares for Mr. S Dingemans (CFO) resulting from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly reports the mechanics of a share plan transaction.
Important Facts for Investors
- Transaction Type: Increase in notional interest in Ordinary Shares via dividend re-investment.
- Executive Involved: Mr. S Dingemans, Chief Financial Officer.
- Transaction Date: July 14, 2016.
- Share Price: £16.285 per share.
- Total Volume: 1,752.078 shares (comprising personal contributions and matching shares).
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).